李贞，陈伟琴，胡骏，等. 中药对念珠菌的抑菌现状及机制研究进展[J]. 上海中医药杂志，2019,53(12): 83-88,92.

李林彬，宁玉梅. 外阴阴道假丝酵母菌病治疗药物剂型的演变探讨[J]. 健康研究，2016, 36(5): 514-516.

SANGUINETTI M, POSTERARO B, LASSFLORL C. Antifungal drug resistance among Candida species: mechanisms and clinical impact[J]. Mycoses, 2015, 58(Suppl 2): 2-13.

ROBBINS N, CAPLAN T, COWEN L E. Molecular evolution of antifungal drug resistance[J]. Annu Rev Microbiol, 2017(71): 753-775.

KAMAI Y, MAEBASHI K, KUDOH M, et al. Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis[J]. Microbiol Immunol, 2004, 48(12): 937-943.

KAKEYA H, MIYAZAKI Y, MIYAZAKI H, et al. Genetic analysis of azole resistance in the Darlington strain of Candida albicans[J]. Antimicrob Agents Chemother, 2000, 44(11): 2985-2990.

FLOWERS S A, COLON B, WHALEY S G, et al. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans[J]. Antimicrob Agents Chemother, 2015, 59(1): 450-460.

STRZELCZYK J K, SLEMP-MIGIEL A，ROTHER M, et al. Nucleotide substitutions in the Candida albicans ERG11 gene of azole-susceptible and azole-resistant clinical isolates[J]. Acta Biochim Pol, 2013, 60(4): 547-552.

FLOWERS S A，BARKER K S，BERKOW E L, et al. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans[J]. Eukaryot Cell, 2012, 11(10): 1289-99.

MARTEL C M, PARKER J E, BADER O, et al. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B[J]. Antimicrob Agents Chemother, 2010, 54(9): 3578-3583.

ALLEN D, WILSON D, DREW R, et al. Azole antifungals: 35 years of invasive fungal infection management[J]. Expert Rev Anti Infect Ther, 2015, 13(6): 787-98.

GUIDA A, LINDSTADT C, MAGUIRE S L, et al. Using RNA-seq to determine the transcriptional landscape and the hypoxic response of the pathogenic yeast Candida parapsilosis[J]. BMC Genomics, 2011, 628 (12): 2-14.

WU Y, WU M, WANG Y, et al. ERG11 couples oxidative stress adaptation, hyphal elongation and virulence in Candida albicans[J]. FEMS Yeast Res, 2018, 18(7): 1-7.

PRASAD R, BANERJEE A, SHAH A H. Resistance to antifungal therapies[J]. Essays Biochem, 2017, 61(1): 157-166.

VERRIER P J，BIRD D，BURLA B, et al. Plant ABC proteins:a unified nomenclature and updated inventory[J]. Trends Plant Sci, 2008, 13(4): 151-159.

PRASAD R, DE WERGIFOSSE P, GOFFEAU A, et al. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals[J]. Curr Genet, 1995, 27(4): 320-329.

PRASAD R, GOFFEAU A. Yeast ATP-binding cassette transporters conferring multidrug resistance[J]. Annu Rev Microbiol, 2012(66): 39-63.

KUMAR A，NAIR R，KUMAR M, et al. Assessment of antifungal resistance and associated molecular mechanism in Candida albicans isolates from different cohorts of patients in North Indian state of Haryana[J]. Folia Microbiol (Praha), 2020, 65(4): 747-754.

BHATTACHARYA S, SOBEL J D, WHITE T C. A combination fluorescence assay demonstrates increased efflux pump activity as a resistance mechanism in azole-resistant vaginal Candida albicans isolates[J]. Antimicrob Agents Chemother, 2016, 60(10): 5858-5866.

TSAO S, RAHKHOODAEE F, RAYMOND M. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance[J]. Antimicrob Agents Chemother, 2009, 53(4): 1344-1352.

ARCHANA K R, SHAH A H, PRASAD R. MFS transporters of Candida species and their role in clinical drug resistance[J/OL]. FEMS Yeast Res, 2016[2020-09-01]. https: //pubmed. ncbi. nlm. nih. gov/27188885https: //pubmed. ncbi. nlm. nih. gov/27188885.

POURAKBARI B, TEYMURI M, MAHMOUDI S, et al. Expression of major efflux pumps in fluconazole-resistant Candida albicans[J]. Infect Disord Drug Targets, 2017, 17(3): 178-184.

PINTO A C C, ROCHA D A S, MORAES D C, et al. Candida albicans clinical isolates from a southwest brazilian tertiary hospital exhibit MFS-mediated azole resistance profile[J/OL]. An Acad Bras Cienc, 2019[2020-09-01]. https: //pubmed. ncbi. nlm. nih. gov/31365653https: //pubmed. ncbi. nlm. nih. gov/31365653.

LOHBERGER A, COSTE A T, SANGLARD D. Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence[J]. Eukaryot Cell, 2014, 13(1): 127-142.

SA-CORREIA I, DOS SANTOS S C, TEIXEIRA M C, et al. Drug: H+ antiporters in chemical stress response in yeast[J]. Trends Microbiol, 2009, 17(1): 22-31.

RIZZO J, STANCHEV L D, DA SILVA V K A, et al. Role of lipid transporters in fungal physiology and pathogenicity[J]. Comput Struct Biotechnol J, 2019(17): 1278-1289.

KHANDELWAL N K, CHAUHAN N, SARKAR P, et al. Azole resistance in a Candida albicans mutant lacking the ABC transporter CDR6/ROA1 depends on TOR signaling[J]. J Biol Chem, 2018, 293(2): 412-432.

TULASIDAS S, RAO P, BHAT S, et al. A study on biofilm production and antifungal drug resistance among Candida species from vulvovaginal and bloodstream infections[J]. Infect Drug Resist, 2018(11): 2443-2448.

HAWSER S P, DOUGLAS L J. Biofilm formation by Candida species on the surface of catheter materials in vitro[J]. Infect Immun, 1994, 62(3): 915-921.

RAMAGE G, RAJENDRAN R, SHERRY L, et al. Fungal biofilm resistance[J/OL]. Int J Microbiol, 2012[2020-09-01]. https: //pubmed. ncbi. nlm. nih. gov/22518145https: //pubmed. ncbi. nlm. nih. gov/22518145.

STEWART P S, FRANKLIN M J. Physiological heterogeneity in biofilms[J]. Nat Rev Microbiol, 2008, 6(3): 199-210.

HELEEN V A, PATRICK V D, TOM C. Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms[J]. Trends Microbiol, 2014, 22(6): 326-333.

DESAI J V, MITCHELL A P. Candida albicans Biofilm Development and Its Genetic Control[J/OL]. Microbiol Spectr, 2015, 3(3)[2020-09-01]. https: //www. ncbi. nlm. nih. gov/pmc/articles/PMC4507287https: //www. ncbi. nlm. nih. gov/pmc/articles/PMC4507287.

NETT J E，SANCHEZ H，CAIN M T, et al. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan[J]. J Infect Dis, 2010, 202(1): 171-175.

WUYTS J, VAN DIJCK P, HOLTAPPELS M. Fungal persister cells: The basis for recalcitrant infections?[J]. PLoS Pathog, 2018, 14(10): 1007301.

MAEBASHI K，KUDOH M，NISHIYAMA Y, et al. A novel mechanism of fluconazole resistance associated with fluconazole sequestration in Candida albicans isolates from a myelofibrosis patient[J]. Microbiol Immunol, 2002, 46(5): 317-326.

ZARNOWSKI R, SANCHEZ H, COVELLI A S, et al. Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis[J/OL]. PLoS Biol, 2018, 16(10)[2020-09-01]. https: //pubmed. ncbi. nlm. nih. gov/30296253https: //pubmed. ncbi. nlm. nih. gov/30296253.

LIU S，HOU Y，CHEN X, et al. Combination of fluconazole with non-antifungal agents: a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery[J]. Int J Antimicrob Agents, 2014, 43(5): 395-402.

KARABABA M, VALENTINO E, PARDINI G, et al. CRZ1, a target of the calcineurin pathway in Candida albicans[J]. Mol Microbiol, 2006(59): 1429-1451.

JIA W，ZHANG H，LI C, et al. The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms[J]. BMC Microbiol, 2016, 16(1): 113.

ZAVREL M, HOOT S J, WHITE T C. Comparison of sterol import under aerobic and anaerobic conditions in three fungal species, Candida albicans, Candida glabrata, and Saccharomyces cerevisiae[J]. Eukaryot Cell, 2013, 12(5): 725-738.

XIAO M, FAN X, CHEN S C, et al.Antifungal susceptibilities of Candida glabrata species complex，Candida parapsilosis species complex and Candida tropical causing invasive candidiasis in china: 3 year national surveillance[J]. J Antimicrob Chemother, 2015, 70(3): 802-810.

杨亚超. 康复新液对单纯性外阴阴道念珠菌病药效和机制研究[D]. 昆明：云南中医药大学，2020.

贾淑林.香莲方对耐药白念珠菌外排泵基因表达影响的研究[D]. 广州：广州中医药大学，2016.